GlaxoSmithKline Pharmaceuticals Limited

Informe acción NSEI:GLAXO

Capitalización de mercado: ₹354.7b

GlaxoSmithKline Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Bhushan Akshikar

Chief Executive Officer (CEO)

₹33.9m

Compensación total

Porcentaje del salario del CEO11.6%
Permanencia del CEO1.4yrs
Participación del CEOn/a
Permanencia media de la dirección2.1yrs
Promedio de permanencia en la Junta Directiva6.1yrs

Actualizaciones recientes de la dirección

Recent updates

With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case

May 05
With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case

GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear

Apr 14
GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear

Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Feb 15
Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?

Jan 18
Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?

GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected

Dec 28
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected

Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today

Oct 05
Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today

Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?

Sep 12
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet

Mar 17
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet

Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?

Sep 02
Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly

Mar 02
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly

The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On

Mar 20
The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On

Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?

Feb 27
Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?

Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?

Feb 06
Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?

What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?

Jan 11
What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain

Dec 06
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain

Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts

Nov 01
Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts

Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield

Oct 29
Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield

What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?

Sep 29
What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?

If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today

Aug 30
If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today

Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?

Aug 02
Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?

It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend

Jul 12
It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend

Is GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) At Risk Of Cutting Its Dividend?

Jul 07
Is GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) At Risk Of Cutting Its Dividend?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Bhushan Akshikar en comparación con los beneficios de GlaxoSmithKline Pharmaceuticals?
FechaCompensación totalSalarioIngresos de la empresa
Dec 31 2023n/an/a

₹5b

Sep 30 2023n/an/a

₹6b

Jun 30 2023n/an/a

₹6b

Mar 31 2023₹34m₹4m

₹6b

Compensación vs. Mercado: La compensación total ($USD407.49K) de Bhushan está en línea con el promedio de empresas de tamaño similar en el mercado Indian ($USD539.67K).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Bhushan con los resultados de la empresa.


CEO

Bhushan Akshikar

1.4yrs

Permanencia

₹33,949,000

Compensación

Mr. Bhushan Akshikar is Managing Director of GlaxoSmithKline Pharmaceuticals Limited from December 1, 2022. He served as Additional Director of GlaxoSmithKline Pharmaceuticals Limited since March 18, 2021...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Bhushan Akshikar
MD & Executive Director1.4yrs₹33.95msin datos
Juby Chandy
Whole-Time Director & CFO2.1yrs₹54.13msin datos
Ajay Nadkarni
VP of Administration & Real Estate and Company Secretaryno data₹11.57msin datos
Amit Pandey
Executive Vice President of Legal2.3yrssin datossin datos
Simrat Sohal
Vice President of Ethics & Compliance1.3yrssin datossin datos
Ransom D'Souza
Executive Vice President of Communications & Government Affairs7.1yrssin datossin datos
Chinmay Sharma
Executive Vice President of Human Resources3.4yrssin datossin datos
Sukanya Choudhary
Executive Vice-President of Regulatory Affairsno datasin datossin datos
Sougato Mitra
Head of Specialtyno datasin datossin datos
Rashmi Hegde
Executive Vice President of Medical2.7yrssin datossin datos
Shourov Mukherjee
Executive Vice-President of Adult Vaccines1.8yrssin datossin datos
Upendra Singh
Executive Vice President of General Medicines1.4yrssin datossin datos

2.1yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de GLAXO se considera experimentado (2 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Bhushan Akshikar
MD & Executive Directorno data₹33.95msin datos
Juby Chandy
Whole-Time Director & CFO2.1yrs₹54.13msin datos
Renu Karnad
Non-Executive Chairperson5.1yrs₹3.55m0.00035%
₹ 1.2m
Manu Anand
Independent Director2yrs₹2.30msin datos
Damodarannair Sundaram
Non-Executive Independent Director14.8yrs₹2.90msin datos
Subesh Williams
Non Executive Director7.1yrssin datossin datos
Pradeep Bhide
Non-Executive Independent Director13.6yrs₹2.85msin datos
Anami Narayan Roy
Non-Executive Independent Director12.5yrs₹2.50msin datos
Sunita Maheshwari
Non-Executive & Independent Director4yrs₹2.40msin datos

6.1yrs

Permanencia media

67.5yo

Promedio de edad

Junta con experiencia: La junta directiva de GLAXO se considera experimentada (6 años de antigüedad promedio).